Skip to Content
Merck
CN

T7205

Tegafur

≥98% (HPLC), powder

Synonym(s):

5-Fluoro-1-(tetrahydro-2-furyl)uracil, Ftorafur, Tegafur

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C8H9FN2O3
CAS Number:
17902-23-7
Molecular Weight:
200.17
NACRES:
NA.77
PubChem Substance ID:
329826861
UNSPSC Code:
12352200
EC Number:
241-846-2
MDL number:
MFCD00012351

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Tegafur, ≥98% (HPLC), powder

InChI key

WFWLQNSHRPWKFK-UHFFFAOYSA-N

InChI

1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)

SMILES string

FC1=CN(C2CCCO2)C(=O)NC1=O

assay

≥98% (HPLC)

form

powder

color

white to off-white

mp

171-173 °C (lit.)

solubility

DMSO: >50 mg/mL

storage temp.

room temp

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Tegafur has been used as an internal standard for the analysis of 5′DFCR (5′deoxyfluorocytidine) and 5′DFUR (5′deoxyfluorouridine) using HPLC techniques. Tegafur has also been used as an internal standard for the chromatographic assay of azidothymidine (AZT).

Biochem/physiol Actions

Tegafur is a pro-drug of 5-fluorouracil, an antimetabolite used as an antineoplastic agent. It has been used as adjuvant chemotherapy for curatively resected colorectal cancer therapy.

Preparation Note

Tegafur is soluble in DMSO at a concentration that is greater than 50 mg/ml.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000494941
0000494938
0000494941
0000494938
0000232768

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Thierry Besnard et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 870(1), 117-120 (2008-06-20)
The 5FU prodrug capecitabine undergoes a 3-step enzymatic conversion, including the conversion of 5'DFRC into 5'DFUR by cytidine deaminase (CDA). The presence of CDA activity in blood led us to analyze the possible ex vivo conversion of 5'DFCR into 5'DFUR
Terence C Tang et al.
Neoplasia (New York, N.Y.), 12(3), 264-274 (2010-03-18)
Hepatocellular carcinoma (HCC) is an intrinsically chemotherapy refractory malignancy. Development of effective therapeutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcutaneous human tumor transplants in immunodeficient mice; however, these do not reproduce the
Li-Feng Liu et al.
Chinese medical journal, 125(11), 1931-1935 (2012-08-14)
The pharmacokinetics of zidovudine (AZT) are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed
Muhammad Wasif Saif et al.
Expert opinion on investigational drugs, 18(3), 335-348 (2009-02-27)
S-1 is an oral fluoropyrimidine that is designed to improve the antitumor activity of 5-fluorouracil (5-FU) concomitantly with an intent to reduce its toxicity. S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or
T Yoshimasu et al.
European journal of dermatology : EJD, 11(1), 54-57 (2001-02-15)
A mixture of uracil and tegafur (UFT) is a common antineoplastic agent in Japan. We report a 64-year-old Japanese woman with discoid lupus erythematosus (DLE)-like lesions which were induced by UFT. After surgery to treat lung cancer, UFT (300 mg/day)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service